Supply of podophyllotoxin (WARTEC) 1.5mg/g cream tube by GlaxoSmithKline Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia and to ensure the safety, quality and efficacy of these goods. The Act aims to protect public health by ensuring that therapeutic goods are of an acceptable standard and that their use does not pose an unacceptable risk to the public. The Therapeutic Goods Administration (TGA), an agency of the Australian Government Department of Health, is responsible for administering the Act. One of the key policy objectives of the Act is to ensure that therapeutic goods are appropriately labelled and that consumers have access to accurate and relevant information about the products they use. In February 2013, the delegate of the Secretary of the Department of Health and Ageing gave consent for the supply of podophyllotoxin (WARTEC) 1.5mg/g cream tube by GlaxoSmithKline Australia Pty Ltd, Melbourne VIC, despite it not fully meeting the requirements for the particulars to be included on the main label as per TGO 69. This consent was subject to certain conditions, including the restriction of the consent to a specific batch of 5500 units, and the requirement that the tube labels be as approved by the TGA except for the orientation of the text. This case highlights the importance of compliance with labelling requirements and the TGA’s role in ensuring that therapeutic goods are appropriately labelled and that consumers have access to accurate and relevant information about the products they use.

Scope and Application

The Therapeutic Goods Act 1989 provides the legislative framework for regulating therapeutic goods in Australia, ensuring their safety, quality, and efficacy. Section 14 and 14A of the Act allow the delegate of the Secretary of the Department of Health and Ageing to give consent for the supply of specific therapeutic goods that do not fully comply with the Therapeutic Goods Order (TGO) provisions. In this instance, the delegate has consented to the supply of 5500 units of batch 040Q of podophyllotoxin (WARTEC) 1.5mg/g cream with an expiry date of January 2016, manufactured by GlaxoSmithKline Australia Pty Ltd. The consent is limited to this particular batch, and the tube labels must have the text intended for the main panel around the side of the tube instead of on the flat face. The consent is subject to strict conditions, ensuring that the product complies with all other requirements of the TGA, and no other changes have been made to the product beyond the label orientation. This consent extends the application of the Act to allow for certain flexibility in the presentation of therapeutic goods while maintaining the overall regulatory standards.

Key Provisions

The Therapeutic Goods Act 1989, specifically sections 14 and 14A, provide the legal framework under which the Secretary of the Department of Health and Ageing may consent to the supply of therapeutic goods that do not fully comply with certain regulations. In this instance, section 14(1) allows the delegate of the Secretary to consent to the supply of the product podophyllotoxin (WARTEC) 1.5mg/g cream, produced by GlaxoSmithKline Australia Pty Ltd, despite it not meeting the labelling requirements set out in paragraph 3(3) of Therapeutic Goods Order (TGO) 69. The consent granted is for a specific batch, 5500 units of batch 040Q with an expiry date of January 2016, and is contingent upon certain conditions being met. Under these conditions, as stipulated in section 15(1) of the Act, the consent is strictly limited to the batch in question, and the tube labels must match those provided in the application. This means that while the printing on the tubes has been rotated approximately 90 degrees, placing the text intended for the main panel on the side of the tube rather than the flat face, no other changes have been made to the product itself. This consent ensures that the product can still be supplied while maintaining regulatory oversight and minimising any potential risks to consumers. The obligations imposed by this consent are quite specific. GlaxoSmithKline Australia Pty Ltd must ensure that only the specified batch of 5500 units is supplied and that the tube labels conform exactly to those provided in the application. This includes the unique orientation of the text, which is a departure from the standard requirements. Additionally, no other modifications to the product are permitted, thereby maintaining the integrity and safety of the therapeutic good as originally approved by the Therapeutic Goods Administration (TGA). Failure to comply with the conditions of this consent can result in significant consequences. While the specific penalties are not detailed in the text, breaches of the Therapeutic Goods Act 1989 can generally lead to both civil and criminal penalties. Civil penalties may include fines and the requirement to rectify any non-compliance, while criminal penalties can result in imprisonment, reflecting the seriousness with which the Act treats violations. The exact penalties would depend on the nature and extent of the breach, but the potential for substantial fines and other legal repercussions underscores the importance of adhering to the specified conditions.